Polidocanol concentration and time affect the properties of foam used for sclerotherapy

Dermatologic Surgery

Volumn 37, Issue 10, 2011, Pages 1448-1455

  Van Deurzen, Brend ^a   Ceulen, Roeland P ^b   Tellings, Sarah S ^c   Van Der Geld, Cees ^a   Nijsten, Tamar ^c  

^a EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^b ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

POLIDOCANOL;

AIR; ARTICLE; CONCENTRATION (PARAMETERS); DOSE TIME EFFECT RELATION; FOAM STABILITY; HALF LIFE TIME; LIQUID; MICROBUBBLE; PARTICLE SIZE; PRIORITY JOURNAL; SCLEROTHERAPY; SYRINGE;

HUMANS; INJECTIONS; POLYETHYLENE GLYCOLS; SCLEROSING SOLUTIONS; SCLEROTHERAPY; SYRINGES; VARICOSE VEINS;

EID: 80053916990     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2011.02095.x     Document Type: Article

References (17)

1. Nijsten T, van den Bos RR, Goldman MP, Kockaert MA, et al,. Minimally invasive techniques in the treatment of saphenous varicose veins. J Am Acad Dermatol 2009; 60: 110-9.
2. van den Bos R, Arends L, Kockaert M, Neumann M, et al,. Endovenous therapies of lower extremity varicosities: a meta-analysis. J Vasc Surg 2009; 49: 230-9.
3. Parsi K, Exner T, Connor DE, Ma DD, et al,. In vitro effects of detergent sclerosants on coagulation, platelets and microparticles. Eur J Vasc Endovasc Surg 2007; 34: 731-40.
4. Monfreux A., Traitement sclerosant des troncs sapheniens et leurs collaterales par la methode MUS. Phlebologie 1997; 351.
5. McAusland S., The modern treatment of varicose veins. Med Press Circ 1939; 404-10.
6. Tessari L., Nouvelle technique d'obtention de la sclero-mousse. Phlebologie 2000; 129.
7. Wollmann JC., Sclerosant foams, stabilities, physical properties and rheological behavior. Phlebologie 2010; 208-17.
8. Rao J, Goldman MP., Stability of foam in sclerotherapy: differences between sodium tetradecyl sulfate and polidocanol and the type of connector used in the double-syringe system technique. Dermatol Surg 2005; 31: 19-22.
9. Gallenkemper G., Schaumveroedung: lange Wiederaufschaeum-barkeit von Polidocanol-Schaeumen. Phlebologie 2008; 10-5.
10. Schramm L., Emulsions, foams and suspensions. Weinheim: Willey-VCH Verlag GmbH & Co; 2005.
11. Cavezzi A, Tessari L., Foam sclerotherapy techniques: different gases and methods of preparation, catheter versus direct injection. Phlebology 2009; 24: 247-51.
12. Peterson JD, Goldman MP., An investigation into the influence of various gases and concentrations of sclerosants on foam stability. Dermatol Surg 2011; 37: 12-7.
13. Ceulen RP, Bullens-Goessens YI, Pi Vandev SJ, Nelemans PJ, et al,. Outcomes and side effects of duplex-guided sclerotherapy in the treatment of great saphenous veins with 1% versus 3% polidocanol foam: results of a randomized controlled trial with 1-year follow-up. Dermatol Surg 2007; 33: 276-81.
14. Hamel-Desnos C, Ouvry P, Benigni JP, Boitelle G, et al,. Comparison of 1% and 3% polidocanol foam in ultrasound guided sclerotherapy of the great saphenous vein: a randomised, double-blind trial with 2 year-follow-up. "The 3/1 Study". Eur J Vasc Endovasc Surg 2007; 34: 723-9; discussion 30.
15. Peterson JD, Goldman MP., An investigation on the influence of glycerin on sclerosant foam stability. Phlebology 2011 Mar 17. [Epub ahead of print].
16. Ceulen RP, Jagtman EA, Sommer A, Teule GJ, et al,. Blocking the saphenofemoral junction during ultrasound-guided foam sclerotherapy-assessment of a presumed safety-measure procedure. Eur J Vasc Endovasc Surg. 2010 Oct 4.
17. Isenberg C., The Science of Soap and Soap Bubbles. Somerset: Woodspring Press Ltd; 1978.